Hadjkacem Faten, Frikha Hamdi, Boujelben Khouloud, Chaari Chiraz, Mnif Emna, Masmoudi Abderrahmen, Boudawara Tahia, Turki Hamida, Abid Mohamed
University of Sfax, Sfax, Tunisia.
Hosp Pharm. 2023 Aug;58(4):357-362. doi: 10.1177/00185787231151861. Epub 2023 Feb 9.
Dipeptidyl peptidase-4 inhibitors (DPP-4i), or gliptins, are a widely used glucose-lowering agents. A growing amount of evidence pointed to a possible role of DPP-4i in the induction of bullous pemphigoid (BP), which is an auto-immune skin blistering disease that mainly affects the elderly. In this article we discuss a case of DPP-4i associated BP and we provide an updated review of the current knowledge regarding this emerging entity. Use of DPP-4i, particularly vildagliptin, was found to significantly increase the risk of BP. BP180 would be in the center of the aberrant immune response. DPP-4i induced BP is thought to be associated with male gender, mucosal involvement, and milder inflammatory phenotype especially in Asian population. Generally, patients may not remit fully after DPP-4i withdrawal only and require either topical or systemic glucocorticoid courses.
二肽基肽酶-4抑制剂（DPP-4i），即格列汀类药物，是广泛使用的降糖药物。越来越多的证据表明DPP-4i在大疱性类天疱疮（BP）的诱发中可能起作用，BP是一种主要影响老年人的自身免疫性皮肤水疱病。在本文中，我们讨论了一例与DPP-4i相关的BP病例，并对有关这个新出现的疾病实体的现有知识进行了更新综述。发现使用DPP-4i，尤其是维格列汀，会显著增加患BP的风险。BP180可能处于异常免疫反应的中心。DPP-4i诱发的BP被认为与男性、黏膜受累以及较轻的炎症表型有关，尤其是在亚洲人群中。一般来说，患者仅停用DPP-4i后可能无法完全缓解，需要局部或全身性糖皮质激素疗程。
